Ophthalmology vertical
Ophthalmology practice acquisitions: a sourcing guide.
Ophthalmology practice acquisitions have quietly become one of the most mature consolidation stories in healthcare private equity, and that maturity is exactly what makes sourcing harder today than it was five years ago. National platforms began rolling up cataract and retina practices as early as 2017, years ahead of the dermatology and dental waves that followed. Most major metros already have at least one ophthalmology MSO with an anchor ambulatory surgery centre and a network of affiliated practices. The obvious targets in the obvious cities have mostly been bought.
That does not mean the opportunity is gone. It means the sourcing problem has moved: from finding any independent practice willing to sell, to finding the right practice in a market a platform has not yet entered, or a subspecialty that has resisted consolidation because it is harder to run under a shared-services model. Buyers who still treat ophthalmology practice acquisitions like a wide-open field waste time competing for the same handful of listed practices every other platform is already bidding on. This guide covers how to find the practices that are not on that list.
Why has ophthalmology consolidated faster than other medical specialties?
Ophthalmology consolidated early because it combines a surgical procedure, cataract extraction, with a built-in referral pipeline that few other specialties have. Optometrists conduct routine eye exams and refer surgical cases to ophthalmologists under co-management arrangements, so a platform that controls both the referral relationships and the surgical centre captures economics at every step. Cataract volume is also demographically driven and highly predictable, rising with an ageing population rather than tracking economic cycles the way elective aesthetic procedures do.
That combination attracted platform capital early, and the largest MSOs have spent nearly a decade building density in major metros. S&P Global reports that PE buyout dry powder still sits above $1 trillion, and a meaningful share of healthcare-focused capital keeps chasing specialty medicine roll-ups, ophthalmology included, even as the easiest deals in top-20 metros are already done.
What makes an ophthalmology practice an attractive acquisition target today?
The most attractive remaining targets share four traits, and none of them is "listed with a broker."
- Underpenetrated geography. Secondary and tertiary metros, and suburban markets adjacent to a platform's footprint, still have independent practices no MSO has approached.
- Surgical volume with ASC ownership. A practice with equity in its ambulatory surgery centre captures the facility fee as well as the professional fee, changing acquisition economics versus a hospital-owned facility.
- Subspecialty depth. Retina and glaucoma subspecialists are harder to recruit and replace than comprehensive ophthalmologists, making an established subspecialty practice more defensible, if harder to integrate.
- Owner-physician succession timing. McKinsey estimates up to $5 trillion in US business value will change hands by 2035, and many practice founders are now inside that window.
| Practice type | Typical EBITDA multiple | Integration ease | Key acquisition risk |
|---|---|---|---|
| Comprehensive, no ASC equity | 4x to 6x | High | Referral concentration |
| Comprehensive with ASC equity | 6x to 9x | Medium | Facility fee reimbursement risk |
| Retina or glaucoma subspecialty | 7x to 10x+ | Low | Physician recruitment scarcity |
How do you source ophthalmology practices before they reach a broker or a competing MSO?
Direct outreach to physician-owners, built from a properly scoped target list, is the only reliable way to reach practices before a broker frames the sale or a rival platform gets there first. Cherry Bekaert's 2025 private equity report puts add-on acquisitions at roughly three-quarters of all PE buyout volume, a sign of how much of this market now runs on platforms actively originating their own pipeline rather than waiting for auctions.
For context on what direct origination produces even in a highly competitive healthcare niche: a healthcare investment bank that DealSource Systems runs origination for reached 14 owner conversations in the first three weeks and 133 within 90 days, detailed at /results.
What does a structured sourcing process for ophthalmology practice acquisitions look like?
A disciplined sourcing programme moves through five steps, and skipping the early ones is the most common reason a roll-up thesis stalls after the first few deals.
The Five-Step Ophthalmology Sourcing Programme
- 1. Define the thesis by subspecialty and geography, not just revenue. Specify comprehensive ophthalmology, retina, glaucoma, or oculoplastics, and name the metros and drive-time radius from any platform site. Revenue-only screens surface practices your integration team cannot absorb.
- 2. Build the target list from NPI and ASC licensing data. Combine National Provider Identifier records with state ambulatory surgery centre licensing filings to flag which practices own facility equity, a detail rarely visible from a website.
- 3. Score for succession readiness and referral network strength. Estimate physician age, partner count, and the depth of optometric co-management relationships. A practice with strong outside referral partners is worth more, and harder to replicate.
- 4. Run sequenced, multi-touch outreach to the highest-priority tier first. Based on Danish Lead Co. / DealSource Systems data across more than 400 origination campaigns, follow-up messages account for more than half of qualified positive replies, so single-touch outreach under-reaches the best targets.
- 5. Qualify on timeline before pitching valuation. The goal of a first conversation is understanding whether the physician is six months or three years from a decision, not presenting a term sheet.
How should outreach to ophthalmology practice owners differ from other healthcare verticals?
Outreach to ophthalmology practice owners needs to speak fluently about ASC economics and optometric referral relationships, because a generic "we acquire medical practices" message signals immediately that the buyer has not done the work. Ophthalmologists in mature MSO markets have already fielded multiple acquisition approaches, so a message that cannot distinguish a facility-owning surgical practice from a comprehensive clinic-only practice gets ignored. See our outreach to business owners guide for the underlying framework, and our dermatology practice acquisitions guide for a comparable specialty consolidation story with a different referral structure.
What are the key risks in ophthalmology roll-up strategies?
The main risks are ASC facility fee dependence, physician recruitment constraints, and co-management relationship transfer, each of which can undo the value of an otherwise well-priced acquisition.
- Facility fee dependence. Practices where most margin comes from the ASC facility fee are exposed to reimbursement changes specific to ambulatory surgery, a different risk profile than a clinic-only practice.
- Physician recruitment scarcity. Retina and glaucoma subspecialists take years of fellowship training, and there is no fast way to backfill a departing subspecialist.
- Co-management transfer risk. Optometric referral relationships are often personal to the founding ophthalmologist. An earnout that ignores referral continuity can see volume drop once the founder steps back.
- Integration pace in a facility-heavy business. Integrating an ASC involves separate licensing and credentialing, which takes longer than shared-services integration for professional-fee-only practices.
For the broader playbook that applies across specialty medicine consolidation, see add-on acquisitions and buy-and-build sourcing, and for the optometry side of the referral relationship, see optometry practice acquisitions.
Conclusion
Ophthalmology practice acquisitions reward buyers who understand that this vertical consolidated early and that the easy targets are gone. The opportunity now sits in underpenetrated geographies, defensible subspecialties, and practices with facility ownership that a broker has not yet listed. A five-step sourcing process, built on real NPI and ASC licensing data rather than a purchased contact list, is what separates a platform still finding its next ten deals from one competing for the same three listings as everyone else.
For the origination infrastructure behind a programme like this, see how it works and our healthcare industry page. To see what direct origination produces at scale, see results.
Key Terms Glossary
Frequently asked questions
What EBITDA multiple do ophthalmology practices sell for?
Independent ophthalmology practices without facility ownership typically transact at 5x to 8x EBITDA. Practices with ASC equity and established retina or glaucoma depth can command materially higher multiples.
Why is ophthalmology considered more consolidated than dermatology or dental?
Ophthalmology platforms began forming as early as 2017, years ahead of the dermatology and dental waves. Most major metros already have an established MSO, which pushes new sourcing toward secondary markets and underserved subspecialties.
What is the difference between comprehensive ophthalmology and subspecialty practices for acquisition purposes?
Comprehensive practices perform routine eye care and general cataract surgery, and integrate easily into a shared-services model. Subspecialty practices such as retina, glaucoma, and oculoplastics require harder-to-recruit fellowship-trained physicians and are more defensible, but more dependent on that physician staying involved.
How important is ASC ownership when evaluating an ophthalmology acquisition target?
It is one of the most important variables. A practice with equity in its ambulatory surgery centre captures facility fee revenue in addition to professional fees. Buyers should verify ASC licensing and ownership directly rather than assuming it from marketing materials.
How do optometric referral relationships affect ophthalmology practice valuation?
Strong, established co-management relationships provide a predictable surgical referral pipeline and reduce reliance on the ophthalmologist's personal reputation alone. Buyers should assess whether referral relationships are institutional or personal to the founding physician, since the latter carries more retention risk.
How do you find ophthalmology practices that have not engaged a broker?
Combine National Provider Identifier data with state ASC licensing filings to build a target list that flags facility ownership, then enrich it with physician age and subspecialty. Direct, personalised outreach, sequenced with follow-up, reaches practices months before they would otherwise reach a broker. See how to build a deal origination function for the underlying process.
What role do independent sponsors play in ophthalmology acquisitions?
Independent sponsors and family offices increasingly target single-site or two-site ophthalmology practices below the size threshold that attracts institutional MSO platforms, particularly in subspecialties where larger platforms are less active.